Contralateral Breast Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers

Graeser, Monika; Engel, Christoph; Rhiem, Kerstin; Gadzicki, Dorothea; Bick, Ulrich; Kast, Karin; Froster, Ursula G.; Schlehe, B.; Bechtold, Astrid; Arnold, Norbert; Preisler-Adams, Sabine; Nestle-Kraemling, Carolin; Zaino, Mohammad; Loeffler, Markus; Kiechle, Marion; Meindl, Alfons; Varga, Dominic; Schmutzler, Rita K.

doi:10.1200/jco.2008.19.9430

Cited by 287 publications

(214 citation statements)

References 18 publications

Supporting

Mentioning

179

Contrasting

Unclassified

Order By: Relevance

“…The survival of breast cancer patients also depends on factors such as genetics, age at diagnosis, stage of the cancer, access to care, weight, physical activity status, alcohol consumption, disease co-morbidities, social, economic, environmental factors, and ethnicity (Graeser et al, 2009;Kwan et al, 2010;Protani et al, 2010;Peairs et al, 2011;Sprague et al, 2011;ACS, 2013). Screening guidelines have also evolved based on the research findings correlating breast cancer-screening and survival times.…”

Section: Introductionmentioning

confidence: 99%

Survival Analysis for White Non-Hispanic Female Breast Cancer Patients

Khan¹,

Saxena²,

Gabbidon³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Survival Analysis for White Non-Hispanic Female Breast Cancer Patients

Khan¹,

Saxena²,

Gabbidon³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…Thus, it is not surprising that certain mutations in the BRCA gene lead to an increased risk for breast cancer as part of a hereditary breast-ovarian cancer syndrome. Women with mutated BRCA1 or BRCA2 gene have up to a 60% risk of developing breast cancer (King et al 2003, Graeser et al 2009). Similarly, 55% increased risk of developing ovarian cancer is observed with BRCA1 mutations and about 25% for women with BRCA2 mutations (King et al 2003).…”

Section: Brca1 and Cancermentioning

confidence: 99%

Staying a Step Ahead of Cancer

Nowsheen¹,

Georgakilas²,

Yang³

2012

Cancer Prevention - From Mechanisms to Translational Benefits

View full text Add to dashboard Cite

“…1,[7][8][9][10] Factors that potentially affect the latter include age at first BC diagnosis (especially when diagnosed at ages <50 years),…”

Section: Introductionmentioning

confidence: 99%

“…[1][2][3][4][5][6] After unilateral BC, the estimated 10-year risk of contralateral BC (CBC) is 29% to 39% for patients with BRCA1-associated BC and 23% to 35% for patients with BRCA2-associated BC. 1,[7][8][9][10] Factors that potentially affect the latter include age at first BC diagnosis (especially when diagnosed at ages <50 years), 7,8,11 adjuvant systemic therapy, 12 and risk-reducing salpingo-oophorectomy (RRSO). 13 In view of these increased BC risks, BRCA1 and BRCA2 mutation carriers are informed about various risk-reducing strategies, consisting of intensive BC surveillance (including magnetic resonance imaging [MRI]), 14,15 chemoprevention, 12,16,17 risk-reducing mastectomy (RRM), [18][19][20][21][22] and/or RRSO.…”

Section: Introductionmentioning

confidence: 99%

The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers

Vencken¹,

Kriege²,

Hooning³

et al. 2012

Cancer

View full text Add to dashboard Cite

BACKGROUND:The objective of this study was to assess the incidence of primary breast cancer (PBC) and contralateral breast cancer (CBC) in patients who had BRCA1/BRCA2-associated epithelial ovarian cancer (OC). METHODS: From the database of the Rotterdam Family Cancer Clinic, patients who had BRCA-associated OC without a history of unilateral breast cancer (BC) (at risk of PBC; n ¼ 79) or with a history of unilateral BC (at risk of CBC; n ¼ 37) were selected. The control groups consisted of unaffected BRCA mutation carriers (n ¼ 351) or mutation carriers who had a previous unilateral BC (n ¼ 294), respectively. The risks of PBC and CBC were calculated using the Kaplan-Meier survival method with death considered as a competing risk event. RESULTS: Women with BRCA-associated OC had lower 2-year, 5-year, and 10-year risks of PBC (3%, 6%, and 11%, respectively) compared with unaffected mutation carriers (6%, 16%, and 28%, respectively; P ¼ .03), although they had a considerably higher mortality rate at similar time points (13%, 33%, and 61%, respectively, vs 1%, 2%, and 2%, respectively; P < .001). In BRCA mutation carriers with a previous unilateral BC, the 2-year, 5-year, and 10-year risks of CBC were nonsignificantly lower in patients with OC than in those without OC (0%, 7%, and 7%, respectively, vs 6%, 16%, and 34%, respectively; P ¼ .06), whereas the mortality rate was higher in patients with OC (19%, 34%, and 55%, respectively, vs 4%, 11%, and 21%, respectively; P < .001). CONCLUSIONS: Patients with BRCA-associated OC had a lower risk of developing a subsequent PBC or CBC than mutation carriers without OC, whereas the risk of dying from OC was greater than the risk of developing BC. These data may facilitate more tailored counseling for this patient subgroup, although confirmative studies are warranted. Cancer 2013;119:955-62. V C 2012 American Cancer Society.KEYWORDS: BRCA, ovarian cancer, primary breast cancer, contralateral breast cancer, risk-reducing mastectomy. INTRODUCTIONWomen who have a germline mutation in the breast cancer susceptibility genes BRCA1 or BRCA2 have substantially elevated risks of developing both breast cancer (BC) and ovarian cancer (OC). It has been estimated that the cumulative 10-year risk of primary BC (PBC) ranges between 6% and 23% for BRCA1/BRCA2 mutation carriers, and the highest risk is observed between ages 40 and 50 years.1-6 After unilateral BC, the estimated 10-year risk of contralateral BC (CBC) is 29% to 39% for patients with BRCA1-associated BC and 23% to 35% for patients with BRCA2-associated BC. 1,[7][8][9][10] Factors that potentially affect the latter include age at first BC diagnosis (especially when diagnosed at ages <50 years),

show abstract

Contralateral Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

Abstract: Contralateral breast cancer risk depends on age at first breast cancer and on the affected BRCA gene, and this risk should be considered in treatment planning.

Cited by 287 publications

References 18 publications

Survival Analysis for White Non-Hispanic Female Breast Cancer Patients

Survival Analysis for White Non-Hispanic Female Breast Cancer Patients

Staying a Step Ahead of Cancer

The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers

Contact Info

Product

Resources

About